Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01275365 · ClinicalTrials.gov registry record · Phase 3

Optimizing Protein Intake in Older Americans With Mobility Limitations

A Phase 3 study of Mobility Limitation, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 3
Development phase
92
Enrollment target
1
Study location

NCT01275365: Completed Phase 3 study of Mobility Limitation, sponsored by Brigham and Women's Hospital.

NCT01275365 is a Phase 3 study of Mobility Limitation that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 92 participants, below the 253-participant average among 28 other Mobility Limitation trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01275365, a Phase 3 study of Mobility Limitation, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 3
Development phase
92 participants
Enrollment target
1
Study location

Study Summary

This will be a randomized, placebo-controlled, parallel group, double blind, clinical trial in community dwelling, older men, 65 years of age or older, who have mobility limitation and low protein intake. The study will have a 2 X 2 factorial design, which will allow us to investigate the effects of dietary protein intake and testosterone separately and together.

Primary Outcome

Primary outcome is change in lean body mass, measured by dual energy X-ray absorptiometry (DXA)

Conditions Studied

Interventions

  • DRUG Testosterone enanthate

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2011-05
Est. Completion 2017-01-19
Phase Phase 3
Brigham and Women's Hospital

937 total trials

What the finished NCT01275365 record still lists

NCT01275365 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 253-participant average among 28 other Mobility Limitation trials with a reported enrollment target (64% lower).

The record links to 1 condition, with Mobility Limitation appearing as the primary indexed condition, and to 1 intervention - of which Testosterone enanthate is the first listed.

NCT01275365 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01275365 about?

NCT01275365 is a clinical study titled "Optimizing Protein Intake in Older Americans With Mobility Limitations". This will be a randomized, placebo-controlled, parallel group, double blind, clinical trial in community dwelling, older men, 65 years of age or older, who have mobility limitation and low protein intake. The study will have a 2 X 2 factorial design, which will allow us to investigate the effects of...

What is the current status of trial NCT01275365?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 92 participants. The study started on 2011-05. Estimated completion is 2017-01-19.

What conditions does trial NCT01275365 study?

This clinical trial studies the following conditions: Mobility Limitation.

What interventions are being tested in trial NCT01275365?

The interventions under investigation include: Testosterone enanthate (DRUG).

Who is sponsoring clinical trial NCT01275365?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01275365 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mobility Limitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01275365's enrollment target sits among peer trials

92 15th of 28 higher than 14 of 28 other Mobility Limitation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mobility Limitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03184545 · 92 participants · Phase 3

    Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome

  • NCT04172532 · 92 participants · Phase 1

    Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

  • NCT04508088 · 92 participants

    Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

  • NCT04840602 · 92 participants · Phase 2

    Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01275365, the US trial registry maintained by the National Library of Medicine. NCT01275365 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.